Contemporary role of nevirapine in HIV treatment

AIDS Reviews

Volumn 14, Issue 2, 2012, Pages 132-144

  Coster, Laura O ^a   Kumar, Princy N ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Efavirenz; Etravirine; Extended release formulation; Nevirapine; NNRTI; Rilpivirine

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NEVIRAPINE; PROTEINASE INHIBITOR;

CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; NEUTROPENIA; PRACTICE GUIDELINE; PREGNANCY; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; VIRUS LOAD; VIVID DREAM;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GUIDELINES AS TOPIC; HIV SEROPOSITIVITY; HUMANS; MALE; NEVIRAPINE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84862572513     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2012. Available at: http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl. pdf [Accessed April 3, 2012].
2. Boehringer Ingelheim Pharmaceuticals Inc. Viramune prescribing information. 2011. Available at: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Viramune/Viramune.pdf [Accessed April 3, 2012].
3. European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 6. 2011. Available at: www.europeanaidsclinicalsociety.org [Accessed April 4, 2012].
4. Kesselring A, Wit F, Sabin C, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009;23:1689-99.
5. Boehringer Ingelheim Pharma GmbH & Co. KG. EU Viramune Prescribing Information. 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/000183/WC500051481.pdf [Accessed April 3, 2012].
6. De Lazzari E, Leon A, Arnaiz J, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 2008;9:221-6.
7. Tilson H, Doi P, Covington D, Parker A, Shields K, White A. The antiretrovirals in pregnancy registry: a fifteenth anniversary celebration. Obstet Gynecol Surv. 2007;62:137-48.
8. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2006;22:321-9.
9. Dieleman J, Jambroes M, Gyssens I, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: the ATHENA cohort. AIDS. 2002;16:737-45.
10. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-63.
11. van den Berg-Wolf M, Hullsiek K, Peng G, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008;9:324-36.
12. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother. 2009;63:380-8.
13. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis. 2008;46:1127-9.
14. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;19:463-71.
15. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther. 2011;16:339-48.
16. Towner W, Kerrigan H, LaRiviere M, et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naïve HIV infected patients: a pilot study. Paper presented at: 7th International Congress on Drug Therapy in HIV Infection; Nov 14-18, 2004; Glasgow, Scotland.
17. Mbuagbaw L, Irlam J, Spaulding A, Rutherford G, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev. 2010;12:CD004246.
18. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8:191-203.
19. Reekie J, Reiss P, Ledergerber B, et al. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med. 2011;12:259-68.
20. Dejesus E, Mills A, Bhatti L, Conner C, Storfer S. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract. 2011;65:1240-9.
21. Weberschock T, Gholam P, Hueter E, Flux K, Hartmann M. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR trial). Eur J Med Res. 2009;14:516-9.
22. McIntyre J, Hughes M, Mellors J, et al. Efficacy of ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among antiretroviral-naïve women in Africa: OCTANE trial 2/ACTG A5208. Presented at: CROI; Feb 16-19, 2010; San Francisco, CA.
23. Lockerman S. Lopinavir/ritonavir+tenofovir/emtricitabine is superior to nevirapine+tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 ("OCTANE"). Paper presented at: CROI; Feb 8-11, 2009; Montreal, Canada.
24. Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16:759-69.
25. Arasteh K, Ward D, Plettenberg A, et al. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med. 2011;13:236-44.
26. Franssen R, Sankatsing R, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009;29:1336-41.
27. Jacobs D, Mebane I, Bangdiwala S, Criqui M, Tyroler H. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
28. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 2001;87:2B-7.
29. Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatmentnaive HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12:374-82.
30. Clotet B, van der Valk M, Negredo E, Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S79-84.
31. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
32. Bergersen B. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs. 2006;66:1971-87.
33. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
34. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-70.
35. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
36. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
37. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811-22.
38. Graham N. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr. 2000;25(Suppl 1):S4-11.
39. Friis-Møller N, Reiss P, Sabin C, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35.
40. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-36.
41. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-9.
42. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504-10.
43. Parienti J, Massari V, Rey D, Poubeau P, Verdon R. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45:263-6.
44. Ward D, Curtin J. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20:542-8.
45. Tohyama J, Billheimer J, Fuki I, et al. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis. 2009;204:418-23.
46. Public Health Services Branch Division of HIV/AIDS Services. New Jersey HIV/AIDS report. 2006. Available at: http://www.state.nj.us/health/aids/ documents/qtr1206.pdf [Accessed April 3, 2012].
47. Fenton K. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007;45(Suppl 4):S213-20.
48. Kirk J, Goetz M. Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc. 2009;57:2129-38.
49. Siervogel R, Wisemandle W, Maynard L, et al. Serial changes in body composition throughout adulthood and their relationships to changes in lipid and lipoprotein levels: the Fels Longitudinal Study. Arterioscler Thromb Vasc Biol. 1998;18:1759-64.
50. Bing E, Burnam M, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-8.
51. Brown L, Tolou-Shams M, Lescano C, et al. Depressive symptoms as a predictor of sexual risk among African American adolescents and young adults. J Adolesc Health. 2006;39:444.
52. Tozzi V, Balestra P, Salvatori M, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
53. Jena A, Sachdeva R, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. Int Assoc Physicians AIDS Care (Chic). 2009;8:318-22.
54. Ribaudo H, Haas D, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS Clinical Trials Group study. Clin Infect Dis. 2006;42:401-7.
55. Pfister M, Labbe L, Hammer S, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS Clinical Trial Group study 398. Antimicrob Agents Chemother. 2003;47:130-7.
56. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
57. Campsmith M, Rhodes P, Hall H, Green T. HIV prevalence estimates-United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:1073-6.
58. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2010. Available at: http://aidsinfo.nih.gov/contentfiles/PerinatalGL-PDA.pdf [Accessed April 3, 2012].
59. Rodriguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Curr HIV Res. 2009;7:526-32.
60. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis. 2010;202:1254-64.
61. Medrano J, Barreiro P, Tuma P, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev. 2008;10:110-5.
62. Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther. 2009;6:22.
63. Hosono N, Chantarangsu S, Kiyotani K, et al. Development of new HLA-B*3505 genotyping method using Invader assay. Pharmacogenet Genomics. 2010;20:630-3.
64. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19:139-46.
65. Waters L, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS. 2007;21:2533-4.
66. Law W, Dore G, Duncombe C, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT cohort, Thailand, 1996-2001. AIDS. 2003;17:2191-9.
67. Haas D, Bartlett J, Andersen J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-6.
68. Labarga P, Soriano V, Vispo M, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670-6.
69. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-9.
70. Mbougua J, Laurent C, Kouanfack C, et al. Hepatotoxicity and effectiveness of a nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health. 2010;10:105.
71. Moore E, Beadsworth M, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect. 2010;61:155-63.
72. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767-74.
73. Berenguer J, Bellon J, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2008;46:137-43.
74. Bristol Myers Squibb Company. Reyataz® (atazanavir sulfate) full prescribing information (Reference ID: 2901063). 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021567s025lbl.pdf [Accessed February 10, 2012].
75. Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, Perez-Ruixo J, Merino E. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol. 2007;63:669-75.
76. McCance-Katz E, Moody D, Morse G, Ma Q, Rainey P. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict. 2010;19:30-7.
77. Ghosn J, Chaix M, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev. 2009;11:165-73.
78. de Bethune M. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010;85:75-90.
79. Plank R, Kuritzkes D. An update on HIV-1 antiretroviral resistance. Curr Opin HIV AIDS. 2006;1:417-23.
80. Gupta R, Hill A, Sawyer A, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47:712-22.
81. Poveda E, Anta L, Blanco J, et al. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS. 2010;24:469-71.
82. Dieleman J, Sturkenboom M, Wit F, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis. 2002;185:1261-8.
83. Martinez E. The NEFA study: results at three years. AIDS Rev. 2007;9:62.
84. Martinez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-46.
85. Schouten J, Krambrink A, Ribaudo H, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010;50:787-91.
86. Barreiro P, Camino N, De Julian R, Gonzalez-Lahoz J, Soriano V. Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better? HIV Clin Trials. 2003;4:244-7.
87. Colafigli M, Di Giambenedetto S, Bracciale L, et al. Long-term follow-up of nevirapine-treated patients in a single-centre cohort. HIV Med. 2009;10:461-9.
88. Gil P, de Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis. 2004;39:1024-9.